Revista Colombiana de Reumatología (English Edition)
Review ArticleNew therapies in osteoporosisNuevas terapias en osteoporosis☆
Section snippets
Methodology
It was conducted a literature review, searching articles of relevance on new therapies in osteoporosis, in order to perform subsequently a broad description of the topic. The review was carried out in the MEDLINE and EMBASE databases. The search strategy did not have date limits and was conducted using MeSH terms as it follows: “osteoporosis AND antiresorptive therapies”, “osteoporosis AND anabolic therapies”, “osteoporosis AND denosumab”, “osteoporosis AND cathepsin k inhibitors”,
Denosumab
Is a fully human monoclonal antibody that has a high affinity for RANKL, a molecule known for its prominent role in osteoclastogenesis.8, 9
Its pharmacokinetic properties are superior, compared with other drugs, which results in a longer dosing interval. It is the most advanced of all the compounds under research and it has been approved in Europe for the treatment of osteoporosis and in the United States for the management of osteoporosis and bone metastases.10
It suppresses, in a dose-dependent
Anabolic therapy
Anabolic drugs improve bone formation rather than avoiding a greater loss of bone mass, and the result is a faster increase in bone mass. Special attention is being paid to the activation of the canonical Wnt bone-forming signaling pathway to achieve an anabolic effect on the bone. The canonical Wnt signaling pathway offers several objectives that may be suitable for pharmacological intervention. The main purpose of this interventions is to increase signaling in order to increase the bone mass (
Conclusions
The number of available anti-osteoporotic drugs will increase considerably in the coming years. Many of the new drugs combine efficacy with convenient administration, which could result in a better adherence. Odanacatib and to some extent saracatinib represent a different class of antiresorptive agents that inhibit the activity of osteoclasts rather than undermining their viability. The successful integration of these new compounds is based on the evidence of osteoporosis therapy that requires
Conflict of interest
The authors declare that they have no conflict of interest.
References (69)
- et al.
New therapeutics for osteoporosis
Curr Opin Pharmacol
(2014) - et al.
Denosumab and bisphosphonates. Different mechanisms of action and effects
Bone
(2011) - et al.
Teriparatide and denosumab, alone or combined, in women with posmenopausal osteoporosis: the DATA study randomised trial
Lancet
(2013) - et al.
Denosumab in breast cancer treatment
Eur J Pharmacol
(2013) Future directions in osteoporosis therapeutics
Endocrinol Metab Clin North Am
(2012)- et al.
Denosumab-related osteonecrosis of the jaw
J Am Dent Assoc
(2012) - et al.
Novel approaches to the treatment of osteoporosis
Best Pract Res Clin Endocrinol Metab
(2014) - et al.
Reduction of nocturnal rise in bone resorption by subcutaneous GLP-2
Bone
(2004) - et al.
Disassociation of bone resorption and formation by GLP-2: a 14-day study in healthy postmenopausal women
Bone
(2007) - et al.
Four-month treatment with GLP-2 significantly increases hip BMD A randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD
Bone
(2009)
Dickkopf- 1 is a key regulator of myeloma bone disease: opportunities and challenges for therapeutic intervention
Blood Rev
Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats
Bone
The assessment of fracture risk
J Bone Joint Surg Am
Determinants of skeletal fragility
Best Pract Res Clin Rheumatol
Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis
Endocr Rev
Bone remodeling increases substantially in the years after menopause and remains increased in older osteoporosis patients
J Bone Min Res
Advances in osteoclast biology resulting from the study of osteopetrotic mutations
Hum Genet
Perspectives on osteoporosis therapies
J Endocrinol Invest
The inhibition of RANK-ligand in the management of postmenopausal osteoporosis and related fractures: the role of denosumab
Gynecol Endocrinol
Denosumab in osteoporosis
Expert Opin Drug Saf
Osteoporosis in men: epidemiology and treatment with denosumab
Clin Interv Aging
A review of denosumab for the treatment of osteoporosis
Patient Prefer Adher
Implications of osteoblast-osteoclast interactions in the management of osteoporosis by antiresorptive agents denosumab and odanacatib
Curr Osteoporos Rep
Denosumab: recent update in postmenopausal osteoporosis
Acta Reumatol Port
Denosumab for prevention of fractures in postmenopausal women with osteoporosis
N Engl J Med
The effect of three or six years of denosumabm exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension
J Clin Endocrinol Metab
Two years of Denosumab and teriparatide administration in posmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial
J Clin Endocrinol Metab
Denosumab in men receiving androgen-deprivation therapy for prostate cancer
N Engl J Med
Effects of denosumab on bone mineral density and bone turnover in posmenopausal women
Pharmacotherapy
Effects of denosumab on fracture and bone mineral density by level of kidney function
J Bone Miner Res
Osteonecrosis of the jaw in a male osteoporotic patient treated with denosumab
Osteoporos Int
Treatment of osteoporosis in renal insufficiency
Clin Rheumatol
Potential role of odanacatib in the treatment of osteoporosis
Clin Interv Aging
Odanacatib in posmenopausal women with low bone mineral density: a review of current clinical evidence
Ther Adv Musculoskelet Dis
Cited by (0)
- ☆
Please cite this article as: Posada AF, Aguirre HD, Casallas JCG, Patiño JDL, Oñate RV. Nuevas terapias en osteoporosis. Rev Colomb Reumatol. 2016;23:34–43.